Deborah T. Gold
Professor in Psychiatry and Behavioral Sciences
In particular, my current research focuses on compliance and persistence with osteoporosis medications. One current study focuses on the impact of race/ethnicity on medication decision making. We are trying to determine the relative weight of cost, convenience, dosing interval, efficacy, and safety in making medication decisions and taking medication on a regular basis as prescribed by a health care provider. I am also on the Steering Committees of two major observational studies with different osteoporosis medications.
Finally, I have worked with voluntary health organizations to translate our research findings into positive real-world outcomes for people with chronic illness. I serve on the Board of Trustees of the National Osteoporosis Foundation and am Chair of its Education Committee. I have also chaired the International Symposium on Osteoporosis (ISO) for the last 8 years.
Whitson, Heather E., et al. “Depressive symptomatology and fracture risk in community-dwelling older men and women..” Aging Clin Exp Res, vol. 20, no. 6, Dec. 2008, pp. 585–92. Pubmed, doi:10.1007/bf03324888. Full Text
Gold, Deborah T., et al. “Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy..” Gend Med, vol. 5, no. 4, Dec. 2008, pp. 374–84. Pubmed, doi:10.1016/j.genm.2008.10.004. Full Text
Kleerekoper, Michael, and Deborah T. Gold. “Osteoporosis prevention and management: an evidence-based review..” Clin Obstet Gynecol, vol. 51, no. 3, Sept. 2008, pp. 556–63. Pubmed, doi:10.1097/GRF.0b013e3181809ae0. Full Text
Silverman, Stuart L., and Deborah T. Gold. “Compliance and persistence with osteoporosis therapies..” Curr Rheumatol Rep, vol. 10, no. 2, Apr. 2008, pp. 118–22. Pubmed, doi:10.1007/s11926-008-0021-x. Full Text
Silverman, Stuart L., et al. “Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies..” South Med J, vol. 100, no. 12, Dec. 2007, pp. 1214–18. Pubmed, doi:10.1097/SMJ.0b013e31815a9685. Full Text
Gold, D. T., and S. L. Silverman. “Compliance and persistence with osteoporosis therapies: We can do better.” Future Rheumatology, vol. 2, no. 5, Oct. 2007, pp. 443–45. Scopus, doi:10.2217/174608184.108.40.2063. Full Text
Cramer, Joyce A., et al. “Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis..” Curr Med Res Opin, vol. 23, no. 10, Oct. 2007, pp. 2369–77. Pubmed, doi:10.1185/030079907X226311. Full Text
Cramer, J. A., et al. “A systematic review of persistence and compliance with bisphosphonates for osteoporosis..” Osteoporos Int, vol. 18, no. 8, Aug. 2007, pp. 1023–31. Pubmed, doi:10.1007/s00198-006-0322-8. Full Text
Gold, Deborah T., and Stuart L. Silverman. “Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?.” Curr Osteoporos Rep, vol. 5, no. 1, Mar. 2007, pp. 3–7. Pubmed, doi:10.1007/bf02938616. Full Text